United States Antimony
Through the investors’ lenses
Each of these investors has said in public what they look at before buying. Click a name to see how this company measures up — a tick where it passes one of their tests, a cross where it does not.
Warren Buffett 1/4
| Measure | UAMY | Checked against | |
|---|---|---|---|
| Owner earnings | $-6.92m | positive | ✗ |
| Return on equity | -24.9% | median 11.7% | ✗ |
| Debt to equity | 0.00x | median 0.79x | ✓ |
| Operating margin | -81.3% | median 15.0% | ✗ |
Passes 1 of 4. To be clear: Warren Buffett has never said anything about United States Antimony. These are the company’s own figures put through the tests he described. What he looks at, and why →
Terry Smith 1/3
| Measure | UAMY | Checked against | |
|---|---|---|---|
| Return on capital employed | -27.7% | median 10.1% | ✗ |
| Cash conversion | — | median 1.78x | — |
| Operating margin | -81.3% | median 15.0% | ✗ |
| Debt to equity | 0.00x | median 0.79x | ✓ |
Passes 1 of 3. To be clear: Terry Smith has never said anything about United States Antimony. These are the company’s own figures put through the tests he described. What he looks at, and why →
Charlie Munger 0/3
| Measure | UAMY | Checked against | |
|---|---|---|---|
| Return on capital employed | -27.7% | median 10.1% | ✗ |
| Return on equity | -24.9% | median 11.7% | ✗ |
| Operating margin | -81.3% | median 15.0% | ✗ |
Passes 0 of 3. To be clear: Charlie Munger has never said anything about United States Antimony. These are the company’s own figures put through the tests he described. What he looks at, and why →
Chuck Akre 1/3
| Measure | UAMY | Checked against | |
|---|---|---|---|
| Return on equity | -24.9% | median 11.7% | ✗ |
| Debt to equity | 0.00x | median 0.79x | ✓ |
| Cash conversion | — | median 1.78x | — |
| Return on equity, sustained | 0 of 10 | 8 of 10 above median | ✗ |
Passes 1 of 3. To be clear: Chuck Akre has never said anything about United States Antimony. These are the company’s own figures put through the tests he described. What he looks at, and why →
Philip Fisher 0/4
| Measure | UAMY | Checked against | |
|---|---|---|---|
| Operating margin | -81.3% | median 15.0% | ✗ |
| Net margin | -73.0% | median 10.2% | ✗ |
| Return on capital employed | -27.7% | median 10.1% | ✗ |
| Operating margin, held or improving | -21.5% | 10-yr median -16.0% | ✗ |
Passes 0 of 4. To be clear: Philip Fisher has never said anything about United States Antimony. These are the company’s own figures put through the tests he described. What he looks at, and why →
Walter Schloss 2/2
| Measure | UAMY | Checked against | |
|---|---|---|---|
| Current ratio | 15.68x | median 1.25x | ✓ |
| Debt to equity | 0.00x | median 0.79x | ✓ |
Passes 2 of 2. To be clear: Walter Schloss has never said anything about United States Antimony. These are the company’s own figures put through the tests he described. What he looks at, and why →
Benjamin Graham 2/3
| Measure | UAMY | Checked against | |
|---|---|---|---|
| Current ratio | 15.68x | 2.00x published | ✓ |
| Long-term debt to working capital | 0.00x | 1.00x published | ✓ |
| Positive earnings, ten years running | 0 yrs | 10 published | ✗ |
Passes 2 of 3. To be clear: Benjamin Graham has never said anything about United States Antimony. These are the company’s own figures put through the tests he described. What he looks at, and why →
Joel Greenblatt 0/1
| Measure | UAMY | Checked against | |
|---|---|---|---|
| Return on capital employed | -27.7% | median 10.1% | ✗ |
Passes 0 of 1. To be clear: Joel Greenblatt has never said anything about United States Antimony. These are the company’s own figures put through the tests he described. What he looks at, and why →
Peter Lynch 1/2
| Measure | UAMY | Checked against | |
|---|---|---|---|
| Debt to equity | 0.00x | median 0.79x | ✓ |
| Net margin | -73.0% | median 10.2% | ✗ |
Passes 1 of 2. To be clear: Peter Lynch has never said anything about United States Antimony. These are the company’s own figures put through the tests he described. What he looks at, and why →
Last usable year: 2023-12-31 — 32 months ago. Nothing filed since gives the figures a payout ratio needs. For a company that once paid, that usually means it stopped.
| Basis | Payout | Why |
|---|---|---|
| GAAP earnings | negative | whyLost $0.0600 per share — no earnings to pay from. |
| Operating cash flow | negative | whyOperations consumed $4.75m of cash. |
| Free cash flow | negative | whyOCF fell $6.28m short of capex — the dividend was not funded from free cash flow. |
Nothing is marked as applying, deliberately — no basis produces a ratio. Earnings, operating cash flow and free cash flow are all negative, so there is no denominator to divide the dividend by. That is not a gap in the data; it is the answer. The dividend was funded from something other than the money the business made this year — borrowing, cash on hand, or asset sales — and the filing will say which.
The arithmetic
- GAAP earnings — dividends declared per share $0.0073 ÷ diluted EPS $-0.0600
- Operating cash flow — dividends paid $788k ÷ operating cash flow $-4.75m
- Free cash flow — dividends paid $788k ÷ (operating cash flow $-4.75m − capex $1.53m)
Where the figures came from
- 10-K/A filed 2025-04-18 · accession 0001654954-25-004433
- 10-K filed 2024-04-12 · accession
0001654954-24-004576
All public at sec.gov — you should not have to take our word for it.
Caveats on this company
- DPS derived from dividends paid ($0.01); no per-share tag filed
Computed straight from SEC XBRL. A number that looks wrong to you is more useful to us than agreement — tell us.
Also on: when it files.
When this changes
Every figure above is recomputed whenever United States Antimony files. The monthly letter carries what filed, what moved, and one finding computed across every company here.